NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $1.51 billion. The enterprise value is $1.76 billion.
Important Dates
The last earnings date was Tuesday, October 28, 2025, before market open.
| Earnings Date | Oct 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 129.39 million shares outstanding. The number of shares has increased by 1.09% in one year.
| Current Share Class | 129.39M |
| Shares Outstanding | 129.39M |
| Shares Change (YoY) | +1.09% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 89.88% |
| Float | 112.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 77.59 |
| PS Ratio | 2.09 |
| Forward PS | 1.92 |
| PB Ratio | 1.79 |
| P/TBV Ratio | 76.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 110.41 |
| PEG Ratio | 1.58 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.91, with a Debt / Equity ratio of 0.49.
| Current Ratio | 3.91 |
| Quick Ratio | 3.27 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 50.86 |
| Debt / FCF | n/a |
| Interest Coverage | -15.29 |
Financial Efficiency
Return on equity (ROE) is -12.99% and return on invested capital (ROIC) is -3.31%.
| Return on Equity (ROE) | -12.99% |
| Return on Assets (ROA) | -3.03% |
| Return on Invested Capital (ROIC) | -3.31% |
| Return on Capital Employed (ROCE) | -5.72% |
| Revenue Per Employee | $322,346 |
| Profits Per Employee | -$51,576 |
| Employee Count | 2,200 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 15.17 |
Taxes
| Income Tax | -522,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.45% in the last 52 weeks. The beta is 1.59, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | -33.45% |
| 50-Day Moving Average | 10.78 |
| 200-Day Moving Average | 8.60 |
| Relative Strength Index (RSI) | 56.06 |
| Average Volume (20 Days) | 1,711,220 |
Short Selling Information
| Short Interest | 9.05M |
| Short Previous Month | 8.42M |
| Short % of Shares Out | 7.00% |
| Short % of Float | 8.02% |
| Short Ratio (days to cover) | 3.25 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $709.16 million and -$113.47 million in losses. Loss per share was -$0.89.
| Revenue | 709.16M |
| Gross Profit | 307.81M |
| Operating Income | -73.06M |
| Pretax Income | -113.99M |
| Net Income | -113.47M |
| EBITDA | -3.44M |
| EBIT | -73.06M |
| Loss Per Share | -$0.89 |
Full Income StatementBalance Sheet
The company has $164.12 million in cash and $410.31 million in debt, giving a net cash position of -$246.19 million or -$1.90 per share.
| Cash & Cash Equivalents | 164.12M |
| Total Debt | 410.31M |
| Net Cash | -246.19M |
| Net Cash Per Share | -$1.90 |
| Equity (Book Value) | 838.29M |
| Book Value Per Share | 6.50 |
| Working Capital | 284.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $13.69 million and capital expenditures -$30.74 million, giving a free cash flow of -$17.05 million.
| Operating Cash Flow | 13.69M |
| Capital Expenditures | -30.74M |
| Free Cash Flow | -17.05M |
| FCF Per Share | -$0.13 |
Full Cash Flow StatementMargins
Gross margin is 43.40%, with operating and profit margins of -10.30% and -16.00%.
| Gross Margin | 43.40% |
| Operating Margin | -10.30% |
| Pretax Margin | -16.07% |
| Profit Margin | -16.00% |
| EBITDA Margin | -0.49% |
| EBIT Margin | -10.30% |
| FCF Margin | n/a |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.09% |
| Shareholder Yield | -1.09% |
| Earnings Yield | -7.51% |
| FCF Yield | -1.13% |
Dividend DetailsAnalyst Forecast
The average price target for NeoGenomics is $11.38, which is -2.57% lower than the current price. The consensus rating is "Buy".
| Price Target | $11.38 |
| Price Target Difference | -2.57% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 15.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
NeoGenomics has an Altman Z-Score of 1.7 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.7 |
| Piotroski F-Score | 4 |
